+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Acadia Pharmaceuticals Inc - logo

Acadia Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease, Phase II trial for the treatment of schizophrenia and Phase II study for the treatment of Alzheimer's disease. The company was founded in 1993 and is headquartered in San Diego, California.

From
From
From
From
Bipolar Disorder Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Bipolar Disorder Therapeutics - Global Strategic Business Report

  • Report
  • November 2024
  • 380 Pages
  • Global
From
Schizophrenia - Pipeline Insight, 2024 - Product Thumbnail Image

Schizophrenia - Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 180 Pages
  • Global
From
From
From
From
Treatment Resistant Depression - Pipeline Insight, 2024 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
CNS Therapeutics - Global Strategic Business Report - Product Thumbnail Image

CNS Therapeutics - Global Strategic Business Report

  • Report
  • November 2024
  • 898 Pages
  • Global
From
Parkinson's Disease Drugs - Global Strategic Business Report - Product Thumbnail Image

Parkinson's Disease Drugs - Global Strategic Business Report

  • Report
  • November 2024
  • 94 Pages
  • Global
From
From
From
From
From
Loading Indicator